Pharmacokinetic Evaluation of Voriconazole Treatment in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration

2011 ◽  
Vol 33 (4) ◽  
pp. 393-397 ◽  
Author(s):  
Jaroslav Radej ◽  
Ales Krouzecky ◽  
Pavel Stehlik ◽  
Roman Sykora ◽  
Jiri Chvojka ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Continuous Venovenous Hemofiltration ◽  
Pharmacokinetic Evaluation

In vivo Elimination of Clonidine by Continuous Venovenous Hemofiltration in Critically Ill Patients

2020 ◽  
Vol 49 (5) ◽  
pp. 622-626
Author(s):  
Huub L.A. van den Oever ◽  
Marieke Zeeman ◽  
Polina Nassikovker ◽  
Carmen Bles ◽  
Fred A.L. van Steveninck ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Continuous Venovenous Hemofiltration ◽  
Kidney Dysfunction ◽  
Sieving Coefficient ◽  
The Mean ◽  
Ventilated Patients

Background: Clonidine is an α2-agonist that is commonly used for sedation in the intensive care unit. When patients are on continuous venovenous hemofiltration (CVVH) in the presence of kidney dysfunction, the sieving coefficient of clonidine is required to estimate how much drug is removed by CVVH. In the present study, we measured the sieving coefficient of clonidine in critically ill, ventilated patients receiving CVVH. Methods: A total of 20 samples of plasma and ultrafiltrate of 3 patients on CVVH, using a standard 1.5 m2 polyacrylonitrile AN69 membrane, during continuous clonidine infusion were collected. After correction for the effect of predilution, we calculated the sieving coefficient for clonidine. Results: The mean sieving coefficient of clonidine was 0.52 (SD 0.097). Conclusion: Using a polyacrylonitrile AN69 membrane in a CVVH machine, the in vivo sieving coefficient of clonidine was 0.52.

45: Pharmacokinetic Evaluation of Cefazolin in the Cerebral Spinal Fluid of Critically Ill Patients

2020 ◽  
Vol 49 (1) ◽  
pp. 24-24
Author(s):  
Alison Novak ◽  
Martin Krsak ◽  
Luis Cava ◽  
Robert Neumann ◽  
Tyree Kiser ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid ◽  
Pharmacokinetic Evaluation

Pharmacokinetic evaluation of fluconazole in critically ill patients

2011 ◽  
Vol 7 (11) ◽  
pp. 1431-1440 ◽  
Author(s):  
Mahipal Sinnollareddy ◽  
Sandra L Peake ◽  
Michael S Roberts ◽  
E Geoffrey Playford ◽  
Jeffrey Lipman ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Pharmacokinetic Evaluation

Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration

1998 ◽  
Vol 26 (1) ◽  
pp. 88-91 ◽  
Author(s):  
Gilles Capellier ◽  
Christian Cornette ◽  
Annie Boillot ◽  
Christiane Guinchard ◽  
Thierry Jacques ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Continuous Venovenous Hemofiltration

scholarly journals Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients

2001 ◽  
Vol 45 (10) ◽  
pp. 2949-2954 ◽  
Author(s):  
Rebecca S. Malone ◽  
Douglas N. Fish ◽  
Edward Abraham ◽  
Isaac Teitelbaum
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Effective Drug ◽  
Continuous Venovenous Hemofiltration ◽  
Drug Concentrations

ABSTRACT The pharmacokinetics of intravenously administered levofloxacin and ciprofloxacin were studied in intensive care unit patients during continuous venovenous hemofiltration (CVVH; four patients received levofloxacin, and five received ciprofloxacin) or hemodiafiltration (CVVHDF; six patients received levofloxacin, and five received ciprofloxacin). Levofloxacin clearance was substantially increased during both CVVH and CVVHDF, while ciprofloxacin clearance was affected less. The results of this study suggest that doses of levofloxacin of 250 mg/day and ciprofloxacin of 400 mg/day are sufficient to maintain effective drug concentrations in the plasma of patients undergoing CVVH or CVVHDF.

Sign in / Sign up

Export Citation Format

Share Document